新型抗精神病药KarXTOA
New antipsychotic drug KarXT
目前抗精神病药主要针对多巴胺受体起作用,对于阴性症状、认知症状的改善有限,存在锥体外系不良反应、代谢综合征、内分泌紊乱等不良反应,部分患者无法耐受.近期 FDA 批准了新型抗精神病药 KarXT(商品名为 Cobenfy)用于治疗成人精神分裂症,该药通过作用于 M1、M4型毒蕈碱乙酰胆碱受体发挥作用.目前临床试验结果表明,KarXT 能改善精神分裂症的阳性症状、阴性症状和认知损害,不良反应主要为胃肠道症状.本文对 KarXT 的药理机制、药代动力学、临床评价、安全性等方面的最新文献进行了综述.
At present,antipsychotic drugs mainly act on dopamine receptors,but the improvement of negative symptoms and cognitive symptoms is lim-ited.There are extrapyramidal adverse reactions,metabolic syndrome,endocrine disorders and oth-er adverse reactions,which some patients can not tolerate.KarXT(trade name Cobenfy),a novel an-tipsychotic drug approved by the FDA for the treat-ment of schizophrenia in adults,acts on M1 and M4 muscarinic acetylcholine receptors(mAChR).The results of current clinical trials have shown that KarXT can improve the positive symptoms,nega-tive symptoms and cognitive impairment of schizophrenia,and the adverse reactions are main-ly gastrointestinal symptoms.This article reviews the latest literature on the pharmacological mecha-nism,pharmacokinetics,clinical evaluation,and safety of KarXT.
刘鑫;刘小琳;周亚楠;翟金国
山东省戴庄医院,济宁 272051,山东山东省戴庄医院,济宁 272051,山东山东省戴庄医院,济宁 272051,山东济宁医学院精神卫生学院,济宁 272067,山东
医药卫生
抗精神病药临床试验药物评价药物相关性副作用和不良反应认知损害
antipsychotic agentsclinical trialdrug evaluationdrug-related side effects and ad-verse reactionscognitive dysfunction
《中国临床药理学与治疗学》 2026 (3)
428-432,5
山东省自然科学基金项目(ZR2017LH036)济宁市重点研发计划项目(2024YXNS200)
评论